November 2, 2026

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Unaudited Financial Results for the quarter and half year ended September 30, 2026

We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 11:43 A.M. (IST) and ended at 02:28 P.M.), the Unaudited Financial Results along with the Statement of Assets and Liabilities and Statement of Cash flows for the quarter and half year ended September 30, 2026 were approved.

We are enclosing herewith the following:

a. Unaudited Financial Results along with the Statement of Assets and Liabilities and Statement of Cash flows for the quarter and half year ended September 30, 2026;
b. Limited Review Report, in respect of the Unaudited Financial Results for the quarter ended and half year September 30, 2026, as furnished by the Statutory Auditors of the Company;

Kindly take the same on record.

Thanking you.

For **Procter & Gamble Health Limited**

Flavia Peter Machado
Digitally signed by Flavia Peter Machado
Date: 2026.11.02 14:38:14 +05'30'

Flavia Machado
Authorized Signatory

Procter & Gamble Health Limited
CIN: L99999MH1967PLC013726
Registered Office: Ground Floor and First Floor,
P&G Plaza, Cardinal Gracias Road, Chakala,
Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000
www.pghealthindia.com

HARIBHAKTI & CO. LLP

Chartered Accountants

Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended)

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended September 30, 2026 and year to date results for the period from April 1, 2026 to September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as "the said Indian Accounting Standard") and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Haribhakti & Co. LLP
Chartered Accountants
ICAI Firm Registration No.103523W/W100048

HARIBHAKTI & CO. LLP MUMBAI CHARTERED ACCOUNTANTS

Sumant Sakhardande
Partner
Membership No.: 034828
UDIN: 26034828KLTSSN4412
Place: Mumbai
Date: November 02, 2026

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026

(₹ in lakhs)

Sr. No.	Particulars	(1) Three months ended 30th September 2026 (Unaudited)	(2) Preceding Three months ended 30th June 2026 (Unaudited)	(3) Corresponding Three months ended 30th September 2025 (Unaudited)	(4) Six months ended 30th September 2026 (Unaudited)	(5) Corresponding Six months ended 30th September 2025 (Unaudited)	(6) Previous Year ended 31st March 2026 (Audited)
1.	**Revenue from Operations**	38 249	36 371	32 492	**74 620**	66 366	140 797
2.	**Other Income**	389	388	495	**777**	898	1 734
3.	Total income (1+2)	38 638	36 759	32 987	75 397	67 264	142 531
	Expenses						
	a) Cost of materials consumed	7 169	8 031	7 813	15 200	13 767	30 733
	b) Purchases of stock-in-trade (Traded goods)	3 144	2 456	1 064	5 600	3 495	7 058
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	244	(865)	(2 037)	(621)	(1 023)	(1 283)
	d) Employee benefits expenses	5 377	6 039	5 388	11 416	10 989	22 256
	e) Depreciation and amortisation expenses	608	602	608	1 210	1 152	2 359
	f) Finance costs	13	14	12	27	24	55
	g) Other expenses	7 078	10 750	8 237	17 828	18 077	36 367
4.	Total expenses (4)	23 633	27 027	21 085	50 660	46 481	97 545
5.	**Profit before exceptional items and tax (3-4)**	**15 005**	**9 732**	**11 902**	**24 737**	**20 783**	**44 986**
6.	Add: Exceptional item (refer note 7)	-	3 180	-	3 180	-	-
7.	Profit before tax (5+6)	15 005	12 912	11 902	27 917	20 783	44 986
8.	**Tax expenses**						
	a) Current Tax	3 595	3 103	3 054	6 698	5 348	11 082
	b) Deferred Tax Charge / (Credit)	259	194	(6)	453	(37)	446
	c)Adjustment of tax relating to earlier periods	-	-	-	-	-	767
	Total tax expenses	3 854	3 297	3 048	7 151	5 311	12 295
9.	Net Profit for the period / year (7-8)	11 151	9 615	8 854	20 766	15 472	32 691
10.	**Other Comprehensive Income**						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains / (losses) on defined benefit plans	(127)	41	323	(86)	236	(38)
	ii.Income tax effect on above	32	(10)	(81)	22	(59)	10
	Other Comprehensive Income, net of tax	(95)	31	242	(64)	177	(28)
11.	Total Comprehensive Income for the period / year (9+10)	11 056	9 646	9 096	20 702	15 649	32 663
12.	Paid-up equity share capital (Face Value ₹ 10/- each)	1 660	1 660	1 660	**1 660**	1 660	1 660
13.	Other equity	-	-	-	-	-	50 795
14.	**Earnings per equity share (of ₹ 10/- each)**						
	***(not annualised)**						
	(a) Basic and Diluted (in ₹) (before exceptional items)	*** 67.18**	*** 38.77**	* 53.34	*** 105.94**	**93.21**	**196.94**
	(b) Basic and Diluted (in ₹) (after exceptional items)	*** 67.18**	*** 57.92**	* 53.34	*** 125.09**	**93.21**	**196.94**

HARIBHAKTI & CO. LLP ★ CHARTERED ACCOUNTANTS ★ MUMBAI

PROCTER & GAMBLE HEALTH LIMITED ★ MUMBAI

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

Notes:

1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on November 2, 2026 and have been subjected to a limited review by the Statutory Auditors of the Company.These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and expressed "Unmodified" conclusion.

2. This Statement has been prepared in accordance with the Companies ("Indian Accounting Standards") Rules, 2015 ("IND AS") prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

3. The Company does not have a subsidiary, an associate or a joint venture as at September 30, 2026.

4. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.

5. The unaudited financial results are available on the website of the Company (www.pghealthindia.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).

6. Previous year's / quarter's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's /quarter's classification.

7. During the quarter ended June 30, 2026, the Company sold its office premises property located at Worli for ₹ 3 334 Lakhs. The carrying amount of the property as at date of sale was ₹ 154 Lakhs. The gain arising from the sale amounting to ₹ 3 180 Lakhs has been disclosed as an exceptional item for the quarter ended June 30, 2026.

8. The Statement of Assets and Liabilities as at September 30, 2026 is attached herewith as Note 1.

9. The Statement of Cash Flows has been prepared under the indirect method as set out in Ind AS -7 on the "Statement of Cash Flows" and is attached herewith as Note 2.

For and on behalf of the Board of Directors of
Procter & Gamble Health Limited

Milind Thatte
Managing Director

Place : Mumbai
Date : November 2, 2026

HARIBHAKTI & CO. LLP * MUMBAI * CHARTERED ACCOUNTANTS

PROCTER & GAMBLE HEALTH LIMITED * MUMBAI *

Procter & Gamble Health Limited

1 Statement of Assets and Liabilities as at September 30, 2026

(₹ in Lakhs)

Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
Assets		
Non-current assets		
Property, plant and equipment	**9,313**	9,097
Capital work-in-progress	**999**	1,359
Investment property	**236**	251
Right -of -use assets	**642**	827
Intangible assets	**41**	47
Financial assets		
(i) Loans	**1,208**	1,223
(ii) Other financial assets	**460**	484
Deferred tax assets (Net)	**2,633**	3,070
Other non-current assets	**6,060**	4,302
Non-current tax assets (Net)	**7,862**	7,849
Total non-current assets	29,454	28,509
Current assets		
Inventories	**13,689**	13,665
Financial assets		
(i) Trade receivables	**17,580**	16,426
(ii) Cash and cash equivalents	**32,286**	17,724
(iii) Bank balances other than (ii) above	**618**	805
(iv) Loans	**196**	209
(v) Other financial assets	**1,587**	1,617
Other current assets	**6,049**	5,024
Assets held for sale	-	156
Total current assets	72,005	55,626
Total assets	1,01,459	84,135
Equity and Liabilities		
Equity		
Equity share capital	**1,660**	1,660
Other equity	64,145	50,795
Total equity	65,805	52,455
Non-current liabilities		
Financial liabilities		
(i) Lease Liabilities	**411**	572
Provisions	**5,406**	5,470
Other non-current liabilities	152	145
Total non-current liabilities	5,969	6,187
Current liabilities		
Financial liabilities		
(i) Trade payables		
(a) total outstanding dues of micro and small enterprises	**426**	639
(b) total outstanding dues of creditors other than micro and small enterprises	**22,675**	18,578
(ii) Lease Liabilities	**310**	357
(iii) Other financial liabilities	**1,697**	2,125
Provisions	**1,161**	1,401
Current tax liabilities (Net)	**2,410**	877
Other current liabilities	**1,006**	1,516
Total current liabilities	29,685	25,493
Total liabilities	35,654	31,680
Total Equity and Liabilities	1,01,459	84,135

HARIBHAKTI & CO. LLP ★ MUMBAI ★ CHARTERED ACCOUNTANTS

PROCTER & GAMBLE HEALTH LIMITED ★ MUMBAI ★

Procter & Gamble Health Limited

2 Statement of Cash Flows for the six months ended September 30, 2026

(₹ in lakhs)

Particulars	Six months ended September 30, 2026	Six months ended September 30, 2025
A. Cash Flows from Operating Activities		
Profit before tax	**27 917**	**20 783**
Adjustments for:		
Net unrealised foreign exchange (Gain)/Loss	(18)	17
Allowance for doubtful receivables/ other assets	(58)	(391)
Provision for Inventory (net of reversals)	-	297
Provision of GST and Rates & Taxes	(267)	835
Depreciation and amortization expense	1 210	1 152
Provision for Impairment	(3 180)	-
Rental income	(229)	(220)
Provision for employee benefits	(203)	68
Loss on sale of property, plant and equipment	94	172
Share-based payment to employees	118	98
Finance costs	27	24
Interest income	(569)	(530)
Operating profit before working capital changes	**24 842**	**22 305**
Working capital adjustments:		
(Increase) in inventories	(24)	(2 093)
(Increase)/Decrease in trade receivables	(1 192)	1 165
(Increase) in financial and other Assets	(2 701)	(1 267)
Increase in trade payables	3 968	622
Increase in other liabilities and provisions	(629)	863
Cash generated from operations	**24 264**	**21 595**
Income taxes paid (net)	(5 178)	(4 372)
Net cash flows generated from operating activities (A)	**19 086**	**17 223**
B. Cash Flows from Investing Activities		
Purchase and construction of property, plant & equipment, capital work-in-progress	(968)	(599)
Proceeds from disposal of property plant & equipment and assets held for sale	3 364	9
Rental income	229	220
Interest received	548	511
Net cash flows generated from investing activities (B)	**3 173**	**141**
C. Cash flow from financing activities		
Dividend paid	(7 470)	(7 470)
Payment of lease liability	(227)	(164)
Net cash flows (used in) financing activities (C)	**(7 697)**	**(7 634)**
Net (decrease) in cash and cash equivalents (A+B+C)	**14 562**	**9 729**
Cash and cash equivalents at the beginning of the period	**17 724**	**18 227**
Cash and cash equivalents at the end of the period	**32 286**	**27 956**
Components of Cash and Cash equivalents at the end of the period		
In Current accounts	**8 316**	**6 956**
In Term deposits (having original maturity of less than three months)	**23 970**	**21 000**
	32 286	**27 956**

HARIBHAKTI & CO. LLP CHARTERED ACCOUNTANTS MUMBAI

PROCTER & GAMBLE HEALTH LIMITED MUMBAI